Therap Adv Gastroenterol

ISSN	1756-283X
ISSN-L	-
IUID	3efbef45d4a64b30a84ba11c77f18d70
Modified	2021-12-10T09:26:30.844Z
Created	2021-12-10T09:26:30.844Z

Year 2021

PubMed DOI Crossref

Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study.

Eriksson C, Rundquist S, Lykiardopoulos V, ..., Halfvarson J, SWIBREG SVEAH Study Group

Therap Adv Gastroenterol 14 (-) 17562848211023386 [2021-07-03; online 2021-07-03]

Affinity Proteomics Uppsala [Service]

SciLifeLab Data Centre

Publications 9.5.1